203 related articles for article (PubMed ID: 34936368)
1. Membrane-Decorated Exosomes for Combination Drug Delivery and Improved Glioma Therapy.
Liang S; Xu H; Ye BC
Langmuir; 2022 Jan; 38(1):299-308. PubMed ID: 34936368
[TBL] [Abstract][Full Text] [Related]
2. Dual-targeting immunoliposomes using angiopep-2 and CD133 antibody for glioblastoma stem cells.
Kim JS; Shin DH; Kim JS
J Control Release; 2018 Jan; 269():245-257. PubMed ID: 29162480
[TBL] [Abstract][Full Text] [Related]
3. Development and Validation of a Targeted Treatment for Brain Tumors Using a Multi-Drug Loaded, Relapse-Resistant Polymeric Theranostic.
Chu W; Houston ZH; Fletcher NL; Huda P; Ahamed M; Lim TX; Day BW; Pinkham M; Thurecht KJ
Biomacromolecules; 2023 Jun; 24(6):2674-2690. PubMed ID: 37143361
[TBL] [Abstract][Full Text] [Related]
4. Heme Oxygenase-1 targeting exosomes for temozolomide resistant glioblastoma synergistic therapy.
Rehman FU; Liu Y; Yang Q; Yang H; Liu R; Zhang D; Muhammad P; Liu Y; Hanif S; Ismail M; Zheng M; Shi B
J Control Release; 2022 May; 345():696-708. PubMed ID: 35341901
[TBL] [Abstract][Full Text] [Related]
5. Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting.
Wang L; Tang S; Yu Y; Lv Y; Wang A; Yan X; Li N; Sha C; Sun K; Li Y
Mol Pharm; 2021 Mar; 18(3):915-927. PubMed ID: 33417456
[TBL] [Abstract][Full Text] [Related]
6. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
Kim SS; Rait A; Kim E; DeMarco J; Pirollo KF; Chang EH
Cancer Lett; 2015 Dec; 369(1):250-8. PubMed ID: 26325605
[TBL] [Abstract][Full Text] [Related]
7. Delivery of siRNA based on engineered exosomes for glioblastoma therapy by targeting STAT3.
Liang SF; Zuo FF; Yin BC; Ye BC
Biomater Sci; 2022 Mar; 10(6):1582-1590. PubMed ID: 35179533
[TBL] [Abstract][Full Text] [Related]
8. Exosomal transfer of long non-coding RNA SBF2-AS1 enhances chemoresistance to temozolomide in glioblastoma.
Zhang Z; Yin J; Lu C; Wei Y; Zeng A; You Y
J Exp Clin Cancer Res; 2019 Apr; 38(1):166. PubMed ID: 30992025
[TBL] [Abstract][Full Text] [Related]
9. Exosomal transfer of miR‑25‑3p promotes the proliferation and temozolomide resistance of glioblastoma cells by targeting FBXW7.
Wang J; Li T; Wang B
Int J Oncol; 2021 Aug; 59(2):. PubMed ID: 34278448
[TBL] [Abstract][Full Text] [Related]
10. Non-invasive transferrin targeted nanovesicles sensitize resistant glioblastoma multiforme tumors and improve survival in orthotopic mouse models.
Sandbhor P; Goda J; Mohanty B; Chaudhari P; Dutt S; Banerjee R
Nanoscale; 2021 Dec; 14(1):108-126. PubMed ID: 34897360
[TBL] [Abstract][Full Text] [Related]
11. Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy.
Song S; Mao G; Du J; Zhu X
Drug Deliv; 2016 May; 23(4):1404-8. PubMed ID: 26203687
[TBL] [Abstract][Full Text] [Related]
12. A Preclinical Investigation of GBM-N019 as a Potential Inhibitor of Glioblastoma via Exosomal mTOR/CDK6/STAT3 Signaling.
Wu ATH; Huang HS; Wen YT; Lawal B; Mokgautsi N; Huynh TT; Hsiao M; Wei L
Cells; 2021 Sep; 10(9):. PubMed ID: 34572040
[TBL] [Abstract][Full Text] [Related]
13. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma.
Zeng A; Wei Z; Yan W; Yin J; Huang X; Zhou X; Li R; Shen F; Wu W; Wang X; You Y
Cancer Lett; 2018 Nov; 436():10-21. PubMed ID: 30102952
[TBL] [Abstract][Full Text] [Related]
14. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
[TBL] [Abstract][Full Text] [Related]
15. Identification of 2-Fluoropalmitic Acid as a Potential Therapeutic Agent Against Glioblastoma.
Jiapaer S; Furuta T; Dong Y; Kitabayashi T; Sabit H; Zhang J; Zhang G; Tanaka S; Kobayashi M; Hirao A; Nakada M
Curr Pharm Des; 2020; 26(36):4675-4684. PubMed ID: 32348209
[TBL] [Abstract][Full Text] [Related]
16. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
Chen Z; Wei X; Shen L; Zhu H; Zheng X
Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
[TBL] [Abstract][Full Text] [Related]
17. Heparanase confers temozolomide resistance by regulation of exosome secretion and circular RNA composition in glioma.
Si J; Li W; Li X; Cao L; Chen Z; Jiang Z
Cancer Sci; 2021 Sep; 112(9):3491-3506. PubMed ID: 34036683
[TBL] [Abstract][Full Text] [Related]
18. Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo.
Yu Z; Zhao G; Xie G; Zhao L; Chen Y; Yu H; Zhang Z; Li C; Li Y
Oncotarget; 2015 Oct; 6(32):32930-43. PubMed ID: 26431379
[TBL] [Abstract][Full Text] [Related]
19. Targeted nano-delivery of chemotherapy via intranasal route suppresses in vivo glioblastoma growth and prolongs survival in the intracranial mouse model.
Sandbhor P; Goda J; Mohanty B; Gera P; Yadav S; Chekuri G; Chaudhari P; Dutt S; Banerjee R
Drug Deliv Transl Res; 2023 Feb; 13(2):608-626. PubMed ID: 36245060
[TBL] [Abstract][Full Text] [Related]
20. Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization.
Garnier D; Meehan B; Kislinger T; Daniel P; Sinha A; Abdulkarim B; Nakano I; Rak J
Neuro Oncol; 2018 Jan; 20(2):236-248. PubMed ID: 29016925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
